<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00171171</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670A2402</org_study_id>
    <nct_id>NCT00171171</nct_id>
  </id_info>
  <brief_title>A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis</brief_title>
  <official_title>A Study of Efficacy and Safety of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Because patients with beta-thalassemia are unable to actively eliminate iron from the body,
      toxic and eventually lethal levels of iron can accumulate as a result of repeated blood
      transfusions. This study will evaluate the efficacy, safety and tolerability of deferasirox.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver Iron Concentration (as measured by biopsy)</measure>
    <time_frame>at baseline and after 1 yeor of ICL670 treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Iron balance, i.e. Total Body Iron Excretion (based on the iron influx as determined by the amount of red cells transfused and the change in total body iron (TBI) stores)</measure>
    <time_frame>after 1 year of ICL670 treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Putative surrogate markers such as serum ferritin serum iron, serum transferrin and transferrin saturation</measure>
    <time_frame>monthly assessments for 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>during 1 year ICL670 treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematology and biochemistry, urinalysis</measure>
    <time_frame>monthly assessments for 1 year ICL670 treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG and Echocardiography</measure>
    <time_frame>6-monthly for 1 year ICL670 treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Beta-Thalassemia</condition>
  <condition>Hemosiderosis</condition>
  <arm_group>
    <arm_group_label>Deferasirox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>deferasirox</intervention_name>
    <arm_group_label>Deferasirox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Beta-thalassemia outpatients with transfusional hemosiderosis and unable to be
             chelated with deferoxamine (DFO) due to DFO being contra-indicated and/or due to
             documented unacceptable toxicity of DFO or documented poor response to DFO despite
             proper compliance, or documented non-compliance to DFO, with serum ferritin ≥ 500
             ng/ml and LIC ≥ 2 mg/Fe/g dw liver

          -  Beta-thalassemia outpatients with transfusional hemosiderosis treated with deferiprone

        Exclusion Criteria:

          -  Means levels of ALT &gt; 300 U/L

          -  Serum creatinine above upper limit of normal

          -  Active hepatitis C or chronic hepatitis B receiving specific treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Taher, Ass.Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>American University of Beirut Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ali Taher</name>
      <address>
        <city>Beirut</city>
        <zip>Riad El Solh 1107 2020</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muscat</city>
        <country>Oman</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Damascus</city>
        <country>Syrian Arab Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Lebanon</country>
    <country>Oman</country>
    <country>Saudi Arabia</country>
    <country>Syrian Arab Republic</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3132</url>
    <description>Results for CICL670A2402 from the Novartis Clinical Trials website</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/20424435</url>
    <description>Results for CICL670A2402 from the Novartis Clinical Trials website</description>
  </link>
  <results_reference>
    <citation>Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, Baladi JF, Habr D, Kriemler-Krahn U, El-Beshlawy A. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial. Acta Haematol. 2010;123(4):220-5. doi: 10.1159/000313447. Epub 2010 Apr 27.</citation>
    <PMID>20424435</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Thalassemia (beta-thal. major)</keyword>
  <keyword>Transfusional hemosiderosis</keyword>
  <keyword>Deferasirox</keyword>
  <keyword>Beta-thalassemia major patients</keyword>
  <keyword>Unable to be chelated with deferoxamine or deferiprone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Hemosiderosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

